Varma Mutual Pension Insurance Co Grows Stock Position in Eli Lilly and Company $LLY

Varma Mutual Pension Insurance Co increased its holdings in Eli Lilly and Company (NYSE:LLY) by 1.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 122,868 shares of the company’s stock after buying an additional 1,400 shares during the period. Eli Lilly and Company comprises about 0.8% of Varma Mutual Pension Insurance Co’s holdings, making the stock its 17th largest position. Varma Mutual Pension Insurance Co’s holdings in Eli Lilly and Company were worth $132,044,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in LLY. Maryland Capital Advisors Inc. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter worth about $25,000. Vermillion & White Wealth Management Group LLC boosted its position in shares of Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after buying an additional 16 shares in the last quarter. 10Elms LLP boosted its position in shares of Eli Lilly and Company by 33.3% in the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after buying an additional 10 shares in the last quarter. Miller Global Investments LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter worth about $33,000. Finally, Hopwood Financial Services Inc. boosted its position in shares of Eli Lilly and Company by 113.6% in the 3rd quarter. Hopwood Financial Services Inc. now owns 47 shares of the company’s stock worth $36,000 after buying an additional 25 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q1 beat-and-raise — Lilly reported a heavy upside quarter (revenue and EPS well above estimates) and raised FY guidance, a core catalyst for investor confidence and the April rally. Read More.
• Positive Sentiment: Major manufacturing commitment — Lilly announced an additional $4.5B in Indiana capital investment, bringing total state commitments since 2020 to over $21B; this expands API and genetic‑medicine capacity to support GLP‑1 and future launches. Read More.
• Positive Sentiment: Oral GLP‑1 (Foundayo) early traction — Foundayo is seeing strong early uptake, expanding prescriber breadth and payer access, which supports sustained revenue growth beyond injectable GLP‑1s. Read More.
• Positive Sentiment: Durable immunology data — Omvoh (mirikizumab) shows multi‑year disease clearance in ulcerative colitis, reinforcing long‑term commercial potential in immunology. Read More.
• Positive Sentiment: Analyst support — Guggenheim reiterated a Buy and set a ~20% price target upside, signaling continued dealer/analyst conviction. Read More.
• Neutral Sentiment: Planned bond issuance chatter — Market reports mention Lilly exploring an ~$8B bond sale to fund M&A/expansion; that raises financing activity but details & uses remain unclear. Read More.
• Neutral Sentiment: International market importance — WSJ notes that global demand (outside the U.S.) is a fast‑growing, underappreciated driver for weight‑loss drugs for both Lilly and peers, implying upside beyond U.S. dynamics. Read More.
• Negative Sentiment: Intensifying competition from Novo Nordisk — Novo’s recent pill launch and guidance raise suggest faster uptake and pricing pressure in the oral GLP‑1 market, a direct headwind to Lilly’s market share and margins. Read More.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $987.52 on Thursday. The firm has a market cap of $929.99 billion, a price-to-earnings ratio of 35.08, a price-to-earnings-growth ratio of 1.08 and a beta of 0.48. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The company’s 50-day moving average is $945.26 and its two-hundred day moving average is $989.70. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same period in the prior year, the firm earned $3.34 EPS. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts expect that Eli Lilly and Company will post 35.58 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Wall Street Analyst Weigh In

LLY has been the topic of several recent research reports. Royal Bank Of Canada initiated coverage on shares of Eli Lilly and Company in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $1,250.00 price objective on the stock. The Goldman Sachs Group upped their target price on shares of Eli Lilly and Company from $1,260.00 to $1,283.00 and gave the company a “buy” rating in a report on Friday, May 1st. Guggenheim restated a “buy” rating and issued a $1,183.00 target price on shares of Eli Lilly and Company in a report on Tuesday. Scotiabank restated an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a report on Thursday, February 5th. Finally, Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,217.59.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.